Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QY201 tablets in non-segmental vitiligo (Phase II, randomized, double-blind, placebo-controlled)
CTR20253365Phase 2Active
- Sponsor
- Origin Biosciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of qy201 in Vitiligo, sponsored by Origin Biosciences. Started Nov 2025; status: active.
02
Drugs
qy201
03
Conditions
Vitiligo
Beyond the preview
Go deeper on CTR20253365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253365.